🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 19 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
31/05/2012 4,08 4,14 3,66 3,90 -4,41% 11,76% 69.000
30/05/2012 4,26 4,26 4,02 4,08 -5,56% 5,63% 54.467
29/05/2012 4,14 4,56 4,14 4,32 +0,00% 10,14% 78.033
25/05/2012 4,38 4,56 4,26 4,32 -1,37% 6,85% 44.583
24/05/2012 4,68 4,68 4,02 4,38 -3,95% 14,10% 105.200
23/05/2012 4,08 4,62 3,90 4,56 +10,14% 17,65% 114.167
22/05/2012 4,02 4,20 4,02 4,14 +2,99% 4,48% 120.000
21/05/2012 3,66 4,08 3,66 4,02 +9,84% 11,48% 175.433
18/05/2012 4,02 4,02 3,48 3,66 -8,96% 13,43% 199.333
17/05/2012 4,20 4,32 4,02 4,02 -6,94% 7,14% 146.450
16/05/2012 4,50 4,68 4,26 4,32 -4,00% 9,33% 89.783
15/05/2012 4,50 4,80 4,44 4,50 -1,32% 8,00% 102.950
14/05/2012 4,56 4,62 4,44 4,56 -1,30% 3,95% 91.633
11/05/2012 4,92 5,04 4,56 4,62 -8,33% 9,76% 162.983
10/05/2012 4,80 5,10 4,74 5,04 +6,33% 7,50% 87.667
09/05/2012 4,86 4,86 4,68 4,74 -3,66% 3,70% 99.533
08/05/2012 4,56 4,92 4,50 4,92 +7,89% 9,21% 198.483
07/05/2012 5,04 5,04 4,56 4,56 -8,43% 9,52% 197.067
04/05/2012 5,10 5,22 4,98 4,98 -2,35% 4,71% 107.867
03/05/2012 5,28 5,34 5,10 5,10 +2,41% 4,55% 191.917
02/05/2012 5,04 5,10 4,98 4,98 -1,19% 2,38% 122.150
01/05/2012 4,98 5,22 4,98 5,04 +1,20% 4,82% 112.967
30/04/2012 5,10 5,28 4,98 4,98 +0,00% 5,88% 156.117
27/04/2012 5,22 5,34 4,98 4,98 -4,60% 6,90% 113.717
26/04/2012 5,28 5,46 5,16 5,22 -1,14% 5,68% 107.633
25/04/2012 5,40 5,40 5,16 5,28 -2,22% 4,44% 238.467
24/04/2012 5,28 5,40 5,22 5,40 +2,27% 3,41% 114.183
23/04/2012 5,34 5,40 5,16 5,28 +0,00% 4,49% 127.667
20/04/2012 5,82 5,82 5,22 5,28 -5,38% 10,31% 153.333
19/04/2012 5,40 5,70 5,40 5,58 +4,49% 5,56% 107.800